Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06511063 · ClinicalTrials.gov registry record · Phase 2

Antiviral Clinical Trial for Long Covid-19

A Phase 2 study of Long COVID, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
Phase 2
Development phase
90
Enrollment target
1
Study location

NCT06511063 is a Phase 2 study of Long COVID that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 90 participants, below the 2,186-participant average among 50 other Long COVID trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06511063, a Phase 2 study of Long COVID, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The trial will test if two repurposed HIV antivirals can reduce symptom burden in adult participants with Long Covid compared to placebo. Viral infection and viral reactivation have been documented in Long Covid. Participants will be randomly allocated to receive antivirals, Truvada (tenofovir disoproxil/emtricitabine, TDF/FTC, Group 1) or Selzentry (Group 2), or a placebo (pill) (Group 3), taken daily for 90 days.

Conditions Studied

Long COVID

Interventions

  • DRUG Placebo
  • DRUG tenofovir disoproxil/emtricitabine
  • DRUG Selzentry

Study Locations (1)

New York

  • The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE) - New York

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2024-10-01
Est. Completion 2026-12
Phase Phase 2

Sponsor

Icahn School of Medicine at Mount Sinai

708 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06511063

The ClinicalTrials.gov registry entry for NCT06511063 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,186-participant average among 50 other Long COVID trials with a reported enrollment target (96% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Long COVID appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06511063 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06511063 about?

NCT06511063 is a clinical study titled "Antiviral Clinical Trial for Long Covid-19". The trial will test if two repurposed HIV antivirals can reduce symptom burden in adult participants with Long Covid compared to placebo. Viral infection and viral reactivation have been documented in Long Covid. Participants will be randomly allocated to receive antivirals, Truvada (tenofovir diso...

What is the current status of trial NCT06511063?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-10-01. Estimated completion is 2026-12.

What conditions does trial NCT06511063 study?

This clinical trial studies the following conditions: Long COVID.

What interventions are being tested in trial NCT06511063?

The interventions under investigation include: Placebo (DRUG), tenofovir disoproxil/emtricitabine (DRUG), Selzentry (DRUG).

Who is sponsoring clinical trial NCT06511063?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06511063 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Long COVID

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Long COVID

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.